Among the major molecular subtypes of breast cancer, triple-negative breast cancer (TNBC) lacks hormone receptors (HR) or human epidermal growth factor receptor-2 (HER-2), resulting in being short of therapeutic targets and tumor metastasis 4. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.